Cizzle Biotechnology 2025 results highlight licensing and clinical progress

CIZ

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has announced the publication of the Company’s Annual Report and Financial Statements for the year ended 31 December 2025.

The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company’s website: https://cizzlebiotechnology.com

Executive Chair’s Statement

I am pleased to present the Annual Report for the year ended 31 December 2025 which has been a period of strategic advancement and commercial momentum for the Group. The year marked a transitional period as we moved from a development-focused organisation towards commercial execution. Our core mission continues to be the transformation of lung cancer outcomes by enabling earlier detection through a costeffective and scalable blood test that measures the CIZ1B biomarker, which has shown high sensitivity for early-stage disease.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Cizzle Bio expands CIZ1B lung cancer testing into San Antonio

Cizzle Bio expands the availability of its CIZ1B lung cancer blood test into San Antonio, adding to its existing...

Cizzle Biotechnology raises £500,000 to support US lung cancer test adoption

Cizzle Biotechnology has conditionally raised £500,000 from existing shareholder Frazer Lang to support the commercial adoption of its CIZ1B...

Cizzle Biotechnology to present CIZ1B lung cancer test advances at SYNLAB Symposium

Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on...

Cizzle Biotechnology gains recognition for lung cancer test

Cizzle Biotechnology has been shortlisted for Best Non-Therapeutic R&D Company of the Year at the One Nucleus Genesis Conference,...

Cizzle Biotechnology revises US payments as lung cancer test rollout advances

Cizzle Biotechnology has agreed revised payment terms with Cizzle Bio Inc, deferring US$1.81 million in guaranteed advance payments to...

Cizzle Bio outlines clinical use and ordering process for CIZ1B lung cancer blood test

Cizzle Bio has outlined clinical applications and ordering procedures for its CIZ1B lung cancer blood test, which is available...

Search